The liver on high alert: a comprehensive review of antibiotic-induced liver injury
Antibiotic-induced liver injury (AILI) is a heterogeneous subset of drug-induced liver injury (DILI) that ranges from self-limited biochemical abnormalities to acute liver failure and chronic cholestatic or autoimmune-like disease. This narrative review critically evaluates clinical and mechanistic evidence across major antibiotic classes while retaining a drug-centered structure. Human HLA associations, drug-specific T-cell responses, delayed onset, and immune-rich histology support adaptive immunity as a unifying framework for many therapeutic-dose idiosyncratic reactions. Direct evidence, however, varies by drug. Linezolid toxicity and historical high-dose intravenous tetracycline injury are better supported as non-idiosyncratic mitochondrial exceptions. Reactive metabolites, oxidative stress, transporter effects, and inflammatory stress may initiate or amplify injury, but cytotoxicity-only, lipopolysaccharide/TNF-α, animal, and organ-on-chip models do not by themselves reproduce clinical idiosyncratic AILI. In practice, management still requires phenotype classification, exclusion of competing causes, structured causality assessment, prompt withdrawal when feasible, severity-based referral, and avoidance of rechallenge. Biomarkers, pharmacogenomics, patient-specific models, microphysiological systems, and artificial intelligence remain investigational and require validation in adjudicated antibiotic-exposed cohorts with tolerant controls.
Authors
- Jiaying Lyu (ORCID: https://orcid.org/0009-0006-8628-384X)
- Xiaokai Guo
- Yisheng He
- Yujian Fan
Institutions
- Chinese University of Hong Kong, Shenzhen (CN)
Publication Details
- Journal
- Scientific Reviews
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1038/s44573-026-00033-x
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 0.00